Xvivo Perfusion AB (publ)
XVIPY · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $14,944 | $8,851 | $5,678 | $4,171 |
| - Cash | $416 | $546 | $247 | $399 |
| + Debt | $34 | $31 | $10 | $6 |
| Enterprise Value | $14,563 | $8,337 | $5,442 | $3,778 |
| Revenue | $822 | $598 | $415 | $258 |
| % Growth | 37.6% | 43.9% | 60.7% | – |
| Gross Profit | $616 | $445 | $297 | $188 |
| % Margin | 75% | 74.5% | 71.5% | 72.9% |
| EBITDA | $111 | $172 | $39 | $39 |
| % Margin | 13.5% | 28.8% | 9.4% | 15.2% |
| Net Income | $172 | $92 | $18 | $8 |
| % Margin | 20.9% | 15.4% | 4.4% | 3.2% |
| EPS Diluted | 1.36 | 0.77 | 0.16 | 0.07 |
| % Growth | 76.6% | 381.3% | 128.6% | – |
| Operating Cash Flow | $111 | $46 | $28 | -$12 |
| Capital Expenditures | -$71 | -$144 | -$131 | -$94 |
| Free Cash Flow | $41 | -$98 | -$103 | -$106 |